News for Ocugen Inc (2H51.BE)

Ocugen Inc. (OCGN) has been explosive this year. Since late December 2020, OCGN ran from a low of just 29 cents to a recent high of $13. Helping, OCGN

Today's Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizer's Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovid's investigational medicine Soticlestat.

Following the market opening Wednesday, the Dow traded down 0.07% to 31,369.29 while the NASDAQ fell 1.22% to 13,196.14. The S&P also fell, dropping ...

OCGN stock is screaming for the top after the company announced positive Phase 3 results from a COVID-19 vaccine.

Shares of Ocugen Inc. undefined soared 31.0% in premarket trading Wednesday, after the biopharmaceutical company said its co-development partner Bharat...

Read more about Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results on Business Standard. Covaxin demonstrates significant immunogenicity against the rapidly emerging variants, says Bharat Biotech CMD

With eight states showing a spike in fresh infections, India is set to start its second phase of covid-19 vaccination from Monday, now extended to senior citizens and people aged 45 and over with co-morbidities.

Krishna Ella, chairman and managing director of Bharat Biotech recently said that the Hyderabad-based vaccine maker will be commissioning its third facility by the end of this week

Read more about Bharat Biotech pursues Covid-19 vaccine approval in over 40 countries on Business Standard. The company has also entered into an agreement with U.S. drug developer Ocugen Inc for the commercialization of COVAXIN in the United States, which has seen the most number of infections in the world

Biotech stocks advanced in the week ended Feb. 12, thanks to broader market strength and company-specific catalysts. Small and mid-cap earnings, m...

Biotech stocks advanced in the week ended Feb. 12, thanks to broader market strength and company-specific catalysts. Small and mid-cap earnings, multiple ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 9) Abbott ...

Today's Daily Dose brings you news about Alterity securing funds for Parkinson's research, the Independent Data Monitoring Committee recommending ERYTECH's pancreatic cancer trial to continue, Ocugen's $23 million registered direct offering, uniQure's Huntington's disease trial, and Tonix Pharma's proposed diagnostic skin test to measure T cell immunity to SARS-CoV-2.

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.53%

Toward the end of trading Monday, the Dow traded up 0.45% to 31,288 while the NASDAQ rose 0.48% to 13,922.14. The S&P also rose, gaining 0.37%...

Toward the end of trading Monday, the Dow traded up 0.45% to 31,288 while the NASDAQ rose 0.48% to 13,922.14. The S&P also rose, gaining 0.37% to ...

Midway through trading Monday, the Dow traded up 0.46% to 31,292.52 while the NASDAQ rose 0.56% to 13,933.76. The S&P also rose, gaining 0.38% to ...

Following the market opening Monday, the Dow traded up 0.61% to 31,338.77 while the NASDAQ rose 0.67% to 13,949.08. The S&P also rose, gaining 0.51% to ...

Pre-open movers U.S. stock futures traded higher in early pre-market trade after recording sharp gains in the previous week. The US economy added 49,000 ...